Find all information regarding ProQR’s corporate governance including the articles of association, code of business conduct and ethics and corporate governance guidelines.
This website contains forward-looking statements about potential therapeutic uses and effects of ProQR Therapeutics’ products, including but not limited to our technologies.
At our offices in Leiden we are advancing our proprietary Axiomer RNA-editing platform technology. Our ProQRians, representing over 30 nationalities, are passionate and driven to change the lives of patients and their loved ones.
ProQR's leadership is a strong team with proven track record. Find out who is on our management team, board of directors and scientific advisory board.
ProQR will host an investor webcast on May 9, 2024 at 8:00 am EDT with members of the ProQR Management Team to highlight the data being presented in the ASGCT 2024 poster session and will also conduct an analyst Q&A session.
ProQR's Annual General Meeting (AGM) of Shareholders will take place on Wednesday, May 22, 2024 at 1630 CET (10:30am EDT) at the offices of Allen & Overy LLP, in Amsterdam, the Netherlands.
ProQR will present new preclinical data for Axiomer, including the first preclinical data for its AX-0810 pipeline program for cholestatic diseases targeting NTCP at the ASGCT Annual Meeting, May 7-11, 2024, in Baltimore, Maryland.